Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10722361 | 1.00 | KMT2A (0.50) | KMT2ADAOALDH1A1CASP3CA12 | |
| SCHEMBL14928651 | 1.00 | KMT2A (0.50) | KMT2ADAOALDH1A1CASP3CA12 | |
| SCHEMBL12431379 | 0.91 | DAO (0.46) | KMT2ADAOALDH1A1NPSR1TAAR1 | |
| SCHEMBL2564113 | 0.86 | CASP3 (0.53) | KMT2AALDH1A1CASP3 | |
| SCHEMBL2564111 | 0.86 | CASP3 (0.53) | KMT2AALDH1A1CASP3 | |
| SCHEMBL15842484 | 0.82 | HDAC7 (0.47) | KMT2ACASP3 | |
| SCHEMBL14928667 | 0.82 | HTT (0.46) | KMT2AALDH1A1MAPK1KDM4E | |
| SCHEMBL11779775 | 0.82 | ALDH1A1 (0.53) | KMT2AALDH1A1CASP3CA12CA9 | |
| SCHEMBL6556194 | 0.81 | SCN2A (0.51) | KMT2AALDH1A1CA12CA9KDM4E | |
| SCHEMBL14928818 | 0.80 | ALDH1A1 (0.41) | KMT2AALDH1A1CASP3CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | BLEAKMAN DAVID (US) | 2004-11-25 | — | — | US | disclosed |
| US-6803484-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20040143020-A1 | Sulfonamide derivatives | AIKINS JAMES ABRAHAM (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1438036-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6720357-B2 | TREATMENT OF CONDITIONS ASSOCIATED WITH GLUTAMATE HYPOFUNCTION, SUCH AS PSYCHIATRIC AND NEUROLOGICAL DISORDERS; N-2-(4-N-(3,5-DIFLUOROBENZAMIDO)PHENYL)PROPYL-2-PROPANESULFONAMIDE | ELI LILLY AND COMPANY | 2004-04-13 | — | — | US | disclosed |
| EP-1390072-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030233015-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1311474-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030092770-A1 | Combination therapy for treatment of depression | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| WO-2003032974-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-1296944-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1292311-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002089848-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 2 DIABETES | ELI LILLY AND COMPANY (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090057-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001090056-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | KMT2A 1162/4885DAO 3105/4885ALDH1A1 1638/4885 |
| US-20030233015-A1 | Sulfonamide derivatives | GRIN2A, GRIN1, SLC1A2 | KMT2A 597/4885DAO 773/4885ALDH1A1 185/4885 |
| US-20040143020-A1 | Sulfonamide derivatives | GRIN2A, GRIN2B, SLC1A2 | KMT2A 515/4885DAO 684/4885ALDH1A1 287/4885 |
| US-20030092770-A1 | Combination therapy for treatment of depression | GRM2, GRIK2, GRIN2A | KMT2A 1214/4885DAO 804/4885ALDH1A1 1232/4885 |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | GABRE, SCN2A, SCN1A | KMT2A 664/4885DAO 769/4885ALDH1A1 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.